BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Retifanlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Retifanlimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06160206-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT06160206)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: Retifanlimab with Bevacizumab a
 nd Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblasto
 ma\nEstimated primary completion: 30 November 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06160206
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04494009-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT04494009)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: PD-1 Inhibitor INCMGA00012 as C
 onsolidation Therapy After Definitive Concurrent Chemoradiotherapy\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04494009
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179160-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT06179160)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: A Study to Evaluate INCB161734 
 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mu
 tation\nEstimated primary completion: 1 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06179160
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06056895-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT06056895)
DESCRIPTION:Retifanlimab\, phase 2\, Merkel Cell Carcinoma.\nStudy: Triple 
 Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory
  Merkel Cell Carcinoma\nEstimated primary completion: 31 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06056895
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: Short-term Fasting Prior to PD-
 1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06320405-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT06320405)
DESCRIPTION:Retifanlimab\, phase 1/2.\nStudy: Axatilimab in Combination Wit
 h Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced 
 or Metastatic Solid Tumors\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06320405
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04438824-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT04438824)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: Palbociclib and INCMGA00012 in 
 People With Advanced Liposarcoma\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04438824
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05345002-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT05345002)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: All-Trans Retinoic Acid (ATRA) 
 Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma\nEstimated primary com
 pletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /retifanlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05345002
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06610682-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT06610682)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: A Trial to Evaluate CSF ctDNA a
 nd Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF
 -altered Glioma\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06610682
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04577014-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT04577014)
DESCRIPTION:Retifanlimab\, phase 1/2.\nStudy: Retifanlimab (Anti-PD-1 Antib
 ody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue 
 Sarcoma\nEstimated primary completion: 29 September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04577014
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149481-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT06149481)
DESCRIPTION:Retifanlimab\, phase 1/2.\nStudy: Phase I/II Study of the Combi
 nation Immunotherapy Regimen: SX-682\, TriAdeno Vaccine\, Retifanlimab and
  IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)\nEst
 imated primary completion: 31 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06149481
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219576-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT07219576)
DESCRIPTION:Retifanlimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Retifanlimab and Ruxolitinib In Solid Malignancies\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/retifanlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07219576
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072612-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 3 readout est. (NCT06072612)
DESCRIPTION:Retifanlimab\, phase 3.\nStudy: Study of the Bria-IMT Regimen a
 nd CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06072612
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04470024-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT04470024)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: Phase Ib Trial of Multivalent A
 utophagosome Vaccine With or Without GITR Agonist\, With Anti-PD-1 Immunot
 herapy in HNSCC\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04470024
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389799-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT06389799)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: A Phase 2\, Open Label Study of
  PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PE
 RELI)\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06389799
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05083754-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT05083754)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: Carmustine Wafer in Combination
  With Retifanlimab and Radiation With/Without Temozolomide in Subjects Wit
 h Glioblastoma\nEstimated primary completion: January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05083754
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06896188-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Retifanlimab: Phase 1 readout est. (NCT06896188)
DESCRIPTION:Retifanlimab\, phase 1.\nStudy: 9-ING-41 Combined With Retifanl
 imab\, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Aden
 ocarcinoma (RiLEY)\nEstimated primary completion: 30 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06896188
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677579-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT07677579)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: NIMBLE-CRC: NeoImmunoModulation
  Before Leveraging Excision in Colorectal Rectal Cancer\nEstimated primary
  completion: 30 August 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/retifanlimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07677579
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765836-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT07765836)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: Vilastobart+Retifanlimab in BRC
 A or PALB2 Deficient PC\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/retifanlimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07765836
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425054-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT07425054)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: ctHPVDNA Response-Adapted Chemo
 radiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07425054
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927998-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20291104
DTEND;VALUE=DATE:20291105
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT07927998)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: A Study of Retifanlimab After C
 hemoradiation in People With Anal Cancer\nEstimated primary completion: 4 
 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retifa
 nlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07927998
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04374305-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT04374305)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: Innovative Trial for Understand
 ing the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUI
 TT-NF2)\nEstimated primary completion: 1 December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04374305
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772245-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Retifanlimab: Phase 2 readout est. (NCT07772245)
DESCRIPTION:Retifanlimab\, phase 2.\nStudy: Trial of Retifanlimab With Tras
 tuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer\nEstimat
 ed primary completion: 31 December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07772245
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468136-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20301025
DTEND;VALUE=DATE:20301026
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT07468136)
DESCRIPTION:Retifanlimab\, phase 1/2.\nStudy: Retifanlimab With or Without 
 Difluoromethylornithine for the Treatment of Progressive High Grade Glioma
 s\nEstimated primary completion: 25 October 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07468136
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472322-2210@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT07472322)
DESCRIPTION:Retifanlimab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: ASTX7
 27 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-
 PD-(L)1\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/retifanlimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07472322
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
